# Reunion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reunion

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.reunionmed.cn
- Total disclosed funding: $46M
- Latest round: Series C (Feb 28, 2026)
- Investors on record: 7

## About

Based in Shanghai, China, and founded in 2018, Shanghai Ruining Biotechnology Co., Ltd., dba Reunion, operates as an innovative drug developer that focuses on medical hydrogels. More than 80% of Ruining's team has PhD and master's degrees, and the core members were from Fortune 500 companies. The founder and chairman, Zhen Pan, worked as a technical expert for DuPont. In February 2026, Reunion raised approximately CNY 100 million in Series C funding co-led by Fudan Innovation Centre and Qiming Venture Partners.
The company focuses on the field of medical hydrogel and has independently developed ready-to-use PEG hydrogel materials. It is able to provide clinical medical solutions such as tumor radiotherapy protection, trauma repair, tumor embolization and innovative anti-tumor drugs.
Reunion’s revenue is generated primarily from commercial sales of approved medical hydrogel devices, hospital procurement and clinical adoption of innovative medical devices, and strategic collaborations with medical institutions and industry partners.

## Funding rounds

- Series C, Feb 28, 2026, $15M — Qiming Venture Partners, Fudan Innovation Centre
- Series B, Jan 24, 2024, $14M — Qiming Venture Partners, Dingxin Capital, Qingdao Guoxin Venture
- Series A, Sep 3, 2022 — Qingdao Guoxin Venture
- Series A, Jan 4, 2022, $16M — Qiming Venture Partners, TigerYeah Capital, Kairos Capital
- Seed, Feb 1, 2021, $1.6M — Yushan Partners

## Investors

- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Seed
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B, Series C
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Kairos Capital — Series A
- Qingdao Guoxin Venture — Series A, Series B
- Dingxin Capital — Series B
- Fudan Innovation Centre (https://capitalatlas.ai/funds/fudan-innovation-centre) — Series C